Skip to main content
Contact Us
Subscribe
E-Edition
80°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Amylyx Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
October 13, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
October 10, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
October 02, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
September 05, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
August 03, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
July 12, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
June 23, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
June 15, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
May 30, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
May 11, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
May 05, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America
April 20, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
April 13, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
March 08, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
March 07, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
February 07, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
February 02, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
November 22, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 10, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
November 03, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
October 11, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
October 06, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Launch of Public Offering
October 04, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
September 29, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
September 14, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
September 07, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.